Cargando…
Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer
BACKGROUND: Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low‐dose bevacizumab‐based regimens were well tolerated and would improve efficacy in MBC patients who had...
Autores principales: | Zhai, Xiaoyu, Hong, Ruoxi, Fan, Ying, Yuan, Peng, Wang, Jiayu, Sang, Die, Chen, Junlin, Zhao, Chunying, Ou, Kaiping, Ma, Fei, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928366/ https://www.ncbi.nlm.nih.gov/pubmed/29575760 http://dx.doi.org/10.1111/1759-7714.12627 |
Ejemplares similares
-
Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
por: Liu, Xiu, et al.
Publicado: (2023) -
Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Zhijun, et al.
Publicado: (2022) -
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
por: Defferrari, Carlotta, et al.
Publicado: (2012) -
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016) -
Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)